Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $100,980.00 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) major shareholder Opaleye Management Inc. sold 33,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $3.06, for a total value of $100,980.00. Following the completion of the sale, the insider now owns 124,250 shares of the company’s stock, valued at approximately $380,205. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Friday, May 17th, Opaleye Management Inc. sold 70,885 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.25, for a total value of $230,376.25.
• On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.09, for a total value of $94,554.00.

Protara Therapeutics Trading Up 1.4 %

NASDAQ TARA opened at $2.80 on Friday. The business’s 50-day moving average price is $3.31 and its 200 day moving average price is $2.73. Protara Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.02. As a group, research analysts anticipate that Protara Therapeutics, Inc. will post -3.56 earnings per share for the current year.

Institutional Investors Weigh In On Protara Therapeutics

A hedge fund recently bought a new stake in Protara Therapeutics stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned approximately 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TARA shares. Oppenheimer upped their price objective on Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Monday, May 6th.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.